ANTIGENICS INC. Restricted Stock Award AgreementRestricted Stock Award Agreement • March 17th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
The undersigned (i) acknowledges that [he/she] has received an award (the “Award”) of restricted stock from Antigenics Inc., a Delaware Corporation (the “Company”) under the 1999 Equity Incentive Plan, as amended (the “Plan”), subject to the terms set forth below and in the Plan; (ii) further acknowledges receipt of a copy of the Plan as in effect on the date hereof, and a current prospectus relating to the Plan, and (iii) agrees with the Company as follows:
SIXTH AMENDMENT TO LEASELease • March 17th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
THIS SIXTH AMENDMENT TO LEASE (the “Sixth Amendment”) is made as of this 16th day of March, 2004, by and between NDNE 9/90 CORPORATE CENTER LLC, a Massachusetts limited liability company, having an address c/o National Development, 2310 Washington Street, Newton Lower Falls, Massachusetts 02462 (the “Landlord”) and ANTIGENICS INC., a Massachusetts corporation, having an address at 630 Fifth Avenue, New York, New York 10111 (the “Tenant”).
CONSENT TO ASSIGNMENT OF LEASEConsent to Assignment of Lease • March 17th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
WHEREAS, NDNE 9/90 Corporate Center LLC (“Landlord”) and Aquila Biopharmaceuticals, Inc. (“Assignor”) have heretofore entered into (i) that certain Lease Agreement dated September 19, 1997 as amended by First Amendment of Lease dated the 17th day of December, 1997, Second Amendment of Lease dated the 14th day of January, 1998, Third Amendment of Lease dated the 3rd day of February, 1998, that Fourth Amendment of Lease dated the 27th day of February, 1998 and Fifth Amendment of Lease dated the 13th day of March, 1998 (said Lease Agreement as so amended is hereafter the “Lease”) with respect to certain space located in a building (the “Building”) known as 175 Crossing Boulevard, Framingham, MA;
Antigenics Consent AgreementConsent Agreement • March 17th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
Re: (a) Sublease Agreement dated July 16, 2002, by and between Antigenics, Inc., a Massachusetts corporation, as sublandlord (“Sublandlord”), and GTC Biotherapeutics, Inc., a Massachusetts corporation, as subtenant (“Tenant”), as amended by First Amendment to Sublease dated March 16, 2004 (as so amended and as affected by that that certain Consent to Sublease dated as of July 18, 2002, among Sublandlord, Tenant and NDNE 9/90 Corporate Center LLC, the “Sublease”), pertaining to certain premises located at 175 Crossing Boulevard, Framingham, Massachusetts (the “Premises”); and
FIRST AMENDMENT TO CONSENT TO SUBLEASEConsent to Sublease • March 17th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO CONSENT TO SUBLEASE (“First Amendment”) dated as of March 16, 2004, is made by and between Antigenics Inc., a Massachusetts corporation having an address of 34 Commerce Way, Woburn, MA 01801, a wholly owned subsidiary of Antigenics Inc., a Delaware corporation formerly known as Aquila Biopharmaceuticals, Inc. (“Sublandlord”), GTC Biotherapeutics, Inc., a Massachusetts corporation having an address at 175 Crossing Boulevard, Suite 410, Framingham, MA 01702 (“Subtenant”) and NDNE 9/90 Corporate Center LLC, a Massachusetts limited liability company, having an address c/o National Development, 2310 Washington Street, Newton Lower Falls, MA 02462 (“Overlandlord”) with respect to the following facts:
Amendment No. 1 to the Exclusive License Agreement of July 1, 1988Exclusive License Agreement • March 17th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
[**] = Portions of this agreement have been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission.
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • March 17th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
This Amended and Restated License Agreement (this “Agreement”) is entered into as of September 1, 2003, by and between Antigenics, Inc., a corporation existing under the laws of Delaware and having its principal place of business at 630 Fifth Avenue, Suite 2100, New York, NY 10111 (“Antigenics”), and Sumitomo Pharmaceuticals Co., Ltd. having its principal place of business at 2-8, Doshomachi 2-Chome, Chuo-ku, Osaka 541-8510, Japan (“Sumitomo”).
